“The present circumstance has exposed some structural weaknesses in the EU’s medicines offer chain as well as a higher dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides explained. She advisable that supply chain issues be addressed in an EU pharmaceutical tactic predicted to get released by the tip https://www.rilife.co/infrastructure/